2024-05-20 05:06:00 ET
Summary
- Amicus Therapeutics has recently seen its shares slide under $10, despite strong revenue growth.
- The company's products, Galafold and Pombiliti + Opfolda, have significant sales potential and are seeing good sales traction.
- Analyst firms are also largely positive on the company's prospects.
- An analysis of Amicus Therapeutics is presented in the paragraphs below.
Today, we put rare disease concern Amicus Therapeutics ( FOLD ) under the spotlight. The shares have recently slid under the $10 a share level, which seems too cheap given the company's revenue growth and movement towards profitability. We dig into recent quarterly results and update our investment analysis on this small-cap name in the paragraphs below....
Read the full article on Seeking Alpha
For further details see:
Amicus Therapeutics: Too Cheap At Under $10 A Share